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a b s t r a c t
Individuals vary in their initial reactions to drugs of abuse in ways that may contribute to the likelihood of
subsequent drug use. In humans, most drugs of abuse produce positive subjective states such as euphoria
and feelings of well-being, which may facilitate repeated use. In nonhumans, many drugs initially increase
locomotor activity and produce discriminative stimulus effects, both of which have been considered to be
models of human stimulant and subjective states. Both humans and nonhumans vary in their sensitivity
to early acute drug effects in ways that may predict future use or self-administration, and some of these
variations appear to be genetic in origin. However, it is not known exactly how the initial responses to
drugs in either humans or nonhumans relate to subsequent use or abuse. In humans, positive effects of
drugs facilitate continued use of a drug while negative effects discourage use, and in nonhumans, greater
genetic risk for drug intake is predicted by reduced sensitivity to drug aversive effects; but whether these
initial responses affect escalation of drug use, and the development of dependence is currently unknown.
Although early use of a drug is a necessary step in the progression to abuse and dependence, other variables may be of greater importance in the transition from use to abuse. Alternatively, the same variables
that predict initial acute drug effects and early use may signiﬁcantly contribute to continued use, escalation and dependence. Here we review the existing evidence for relations between initial direct drug
effects, early use, and continued use. Ultimately, these relations can only be determined from systematic
longitudinal studies with comprehensive assessments from early drug responses to progression of problem drug use. In parallel, additional investigation of initial responses in animal models as predictors of
drug use will shed light on the underlying mechanisms.
© 2012 Elsevier Ltd. All rights reserved.
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1. Introduction
Most drugs of abuse produce subjective feelings of well-being
and euphoria in humans, which are thought to contribute to the
drug’s potential to be used or abused (de Wit and Grifﬁths, 1991;
Fischman and Foltin, 1991). Indeed, drug-induced changes in mood
or subjective state have long been the primary indicator of abuse
potential used by the Food and Drug Administration (FDA) to assess
the likelihood of abuse for new medications (Jasinski, 1991; FDA
guidelines in Balster and Bigelow, 2003; Carter and Grifﬁths, 2009).
Drugs that produce euphoria are more likely to be abused than
drugs that fail to produce euphoria, and individuals who report
experiencing more positive effects from a drug are more likely to
use the drug again. However, the extent to which either the quality or magnitude of responses to the ﬁrst few exposures to a drug
are indicators of the individual’s likelihood of continued use, or
in the longer term to abuse or dependence, remains to be determined. The full clinical manifestation of drug dependence results
from dynamic changes that occur only after repeated administration of the drug, including alterations related to learning, tolerance,
cognitive function, stress, sensitization and complex neuroadaptations underlying these phenomena (Everitt et al., 2008). Thus, the
relationship between early subjective responses and fully developed dependence is at best indirect (Wagner and Anthony, 2002).
Yet, there is evidence that an individual’s initial responses to drugs
may constitute one factor contributing to the risk for future abuse
or dependence. This is of particular interest because of the possibility that genetic factors may inﬂuence these initial responses, and
thus impart vulnerability to future use.

2. Individual differences in responses to drugs
Individuals may differ in their responses to drugs on several
dimensions, any of which may inﬂuence subsequent use. Individuals may differ in how the drug makes them feel (i.e., the
subjective self-reported states in humans; discriminative stimulus
effects in animals), how it affects physiological processes (e.g., heart
rate; body temperature) or how it affects their behavior (e.g., risktaking behavior in humans; locomotor activation or depression in
rodents). Further, responses to drugs may vary in magnitude (i.e.,
greater or lesser sensitivity), the quality of effects (e.g., stimulantlike or sedative-like), the affective valence of the effects (e.g., liking,
disliking), and the time course (e.g., onset or duration). These variations in acute drug effects may be genetic or nongenetic in origin.
Further, several of these dimensions have been implicated in the
etiology of drug abuse or dependence. For example, Conrod et al.
(2001) suggest that the amount of increase in heart rate after alcohol is a positive indicator of risk for abuse, and Schuckit (1987) and
others have suggested that low level of intoxication-like response
to alcohol is a risk factor for future alcohol dependence. Evidence
for the causal role of these potential predictors is difﬁcult to obtain
in humans. In nonhumans, there is also a literature examining
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the relation between initial responses to drugs and future drug
self-administration (see below). Advantages of the animal models
include the degree of control over the animals’ drug use history, and
the capacity to manipulate genetic variables. Although a comprehensive review of the nonhuman mammalian literature is beyond
the scope of the present analysis, we note some interesting similarities between humans and nonhumans. It is also important to
mention that a potential source of variability affecting both initial responses to drugs and progression to use is variation in the
pharmacokinetic properties of a drug. For example, there is genetic
variation in the rate at which certain drugs are metabolized, which
may affect sensitivity to drug effects and either increase or decrease
their risk for using the drug (Edenberg, 2007; Ho and Tyndale,
2007). The most common example of this factor is in the ﬂushing
response to alcohol, which decreases risk for developing alcoholism
(see below).

2.1. Methods for studying the role of initial responses in humans
Information about the relationship between sensitivity to initial drug effects and subsequent use in humans can be obtained
from several sources, including retrospective studies with established drug users, longitudinal studies with early drug users, and
laboratory-based studies involving drug choice. In retrospective
studies, drug abusers are asked to recall their early drug use experiences (e.g., Haertzen et al., 1983). For some drug classes, these
retrospective studies provide the only available source of information (e.g., opiate drugs in opiate abusers). However, retrospective
studies are limited by their reliance on memory and highly selective
bias in respondents, who are usually drug users with many years of
drug experience. In prospective studies, initial responses to drugs
are assessed in young early or non-users, and then their recreational
use is followed over months or years (e.g., studies of early cigarette
smokers (Chen et al., 2003; described below)). These studies are
especially valuable because they provide a measure of initial drug
response, not biased by memory. However, they are expensive and
time-consuming, and are not possible for certain drug classes (e.g.,
illicit opiates). A further limitation of both retrospective and longitudinal studies is that initial drug effects are experienced under
naturalistic conditions where expectancies, other concurrent drug
use, and context can inﬂuence the apparent drug effect. In contrast,
in human laboratory studies, participants receive controlled doses
of drugs and are then allowed to consume and regulate their intake
of the drug (Chutuape and de Wit, 1994; de Wit, 1998). These studies often document the participants’ ﬁrst experience with the drug,
unconfounded by expectancies or contextual factors. Participants
who report experiencing positive subjective drug effects (e.g., liking or euphoria) typically choose to consume the drug when given
the opportunity. This concordance provides support for the idea
that greater positive acute effects predict repeated use of the drug
within the laboratory setting, and perhaps outside the laboratory
as well. The measures of subjective drug effects are sensitive and
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reliable. Yet, in the context of opiate drugs, McAuliffe (1975)
noted that subjective drug experiences are sometimes difﬁcult to
deﬁne, and subjects’ ratings of positive effects such as ‘euphoria’,
‘intoxication’, ‘high’ and ‘liking’ of the drug, may not be readily distinguishable from their ratings of apparently negative effects such
as ‘nausea’, ‘sick’, ‘heavy’. Further, especially in the context of initially unpleasant drugs, users may ‘learn to get high’, and adapt
to unpleasant side effects of the drug with repeated use. Thus, initially unpleasant subjective responses to certain drugs may become
positive after relatively few uses.
2.2. Methods for studying the role of initial responses in
nonhumans
Several experimental approaches have been taken to study the
relationship between initial drug effects and use in nonhumans.
Individual variation in sensitivity to initial drug effects (e.g., locomotor behavior, sedative effects) can be examined in relation to
likelihood of initiating drug intake or amount consumed (e.g.,
Piazza et al., 1989; Pierre and Vezina, 1997). These studies provide some evidence that initial drug responses predict future use.
However, many of the existing studies used genetically heterogeneous populations (parallel to unselected populations of humans),
making it difﬁcult to discern the speciﬁc roles of genetic and nongenetic factors in sensitivity. Moreover, these studies sometimes
entail some initial drug exposure to identify a predictor trait, and
this exposure itself could affect the subsequent intake measure. An
alternative approach to studying the relation between initial drug
responses and drug intake, which avoids this problem, is to utilize
genetically deﬁned types of animals to examine genetic correlations between acute drug responses and drug self-administration
(e.g., Kamens et al., 2005). For example, this approach can be taken
using panels of inbred mouse and rat strains, selectively bred lines
of rodents and animals in which single genes have been manipulated. These studies may reveal common genetic factors that
inﬂuence both initial sensitivity and drug intake.
3. Speciﬁc examples of acute responses predicting use or
abuse
The extent to which sensitivity to acute drug effects in humans
predicts the trajectory of drug use outside the laboratory remains
to be determined. Clearly, a multitude of other factors contribute
to the etiology of drug abuse and dependence, including non-drugrelated factors such as stress and impulsivity, and drug factors that
only come into play after repeated ingestion of the drug in a speciﬁc
context such as conditioning, tolerance and sensitization (Everitt
et al., 2008). Recognizing that the initial reaction to a drug is but one
of many factors that contribute to compulsive drug use, we evaluate evidence in humans and nonhumans that the initial drug effects
contribute to subsequent regular use of alcohol, nicotine, cannabis,
cocaine, caffeine and opiates. These drugs are included because they
are among the most commonly used or abuse drugs for which pertinent data are available. Other drug classes, such as hallucinogens,
benzodiazepines, barbiturates, inhalants and dissociative anesthetics will not be discussed because there is not enough information
available.
We review evidence from both humans and nonhuman models. The concordance from human to nonhuman ﬁndings depends
on the sensitivity and validity of the nonhuman models used. As
noted in several recent reviews examining the consilience between
rodent models and human measures of sensitivity to alcohol or
nicotine (Crabbe et al., 2010; O’Dell and Khroyan, 2009; Stephens
et al., 2011), there is a need for more reﬁned measures in animals to
match the measures used with humans. Nevertheless, we review
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the existing evidence from the nonhuman models to address the
speciﬁc question, i.e., do initial responses to drugs predict future
use? This information will provide a context for studying variability in early drug responses, related to both genetic and non-genetic
factors, in relation to continued use (e.g., Haberstick et al., 2011;
Lott et al., 2005).
3.1. Alcohol
3.1.1. Evidence from humans
One well-documented source of variation in acute responses
to alcohol stems from metabolic differences related to enzymes
involved in the degradation of alcohol (Edenberg, 2007). Certain individuals, notably those of East Asian descent, experience
an aversive facial ﬂushing response after consuming alcohol, a
response that can also include nausea, discomfort and tachycardia.
The response is due to accumulation of the metabolite acetaldehyde, which can occur either from more rapid oxidation of alcohol
by alcohol dehydrogenase (ADH) or from slower oxidation of
acetaldehyde by aldehyde dehydrogenase (ALDH). Several genetic
variants have been identiﬁed that affect both of these enzymes,
and individuals affected by the ﬂushing response have a markedly
lower probability of developing alcoholism, presumably because
of the aversive effects they experience after consuming alcohol
(Edenberg, 2007; Whitﬁeld, 2002).
There is also well-described individual variation in the pharmacodynamic proﬁle of alcohol. Most of the studies that have
examined acute responses to alcohol as predictors of future alcohol use focus on young adults with a family history of alcoholism,
but who have not yet themselves developed the disorder. Alcohol
abuse and dependence are highly heritable, such that children of
alcoholics are 4–5 times more likely to become alcoholic themselves (Schuckit, 1985a). The processes that mediate this risk are
not understood, but one approach has been to compare responses
to an acute dose of alcohol in individuals with or without a family history of alcoholism, while they are young and presumably
at risk but not yet dependent. Schuckit and his colleagues have
conducted an elegant series of studies addressing this question,
demonstrating that sons of alcoholics exhibit a distinctive “low
level of response” to certain effects of alcohol (Schuckit, 1984a,b,
1994). They found that sons of alcoholic fathers report less subjective intoxication and body sway after a moderate dose of alcohol
than men without alcoholic relatives. These at-risk individuals also
exhibit less alcohol-induced body sway (Schuckit, 1985b, 1988),
smaller alcohol-induced alterations in cortisol, prolactin, and ACTH
levels, less intense changes in the P300 component of the eventrelated potential and differential EEG effects (Ehlers and Schuckit,
1990; Schuckit, 1988; Schuckit et al., 1987a,b; Schuckit and Gold,
1988). The reduced level of response also occurs in daughters whose
fathers have a history of alcohol dependence (Eng et al., 2005). From
these data, Schuckit and colleagues proposed a low-level response
theory. Individuals who are insensitive to these effects of alcohol are
postulated to be more susceptible to future alcohol use, and ultimately abuse, because they are unable to gauge their own level of
intoxication, and because they need greater amounts of alcohol to
achieve the desired effects. In support of this idea, Schuckit (1994)
conducted a 10-year follow-up study showing that a low response
to alcohol predicted a four-fold increase in likelihood of developing future Alcohol Dependence (APA, 1994). These studies indicate
that lesser responses to alcohol, including certain subjective and
physiological responses, represent a risk factor not only for alcohol
use, but also for future alcohol abuse or dependence. However, as
noted next, alternatives to this theory have also been proposed.
An alternative to Schuckit’s low-level response theory was proposed by Newlin and Thomson (1990), and recently re-examined
by Newlin and Renton (2010). These authors cite 36 studies in
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which high-risk family history positive individuals demonstrated
higher levels of early alcohol response compared to low-risk groups,
on measures ranging from subjective reports of alcohol effects
(e.g., stimulation, intoxication), to physiological effects (e.g., heart
rate and cortisol) and behavioral measures (e.g., memory impairment). The authors noted that the studies that reported greater
effects typically measured responses very soon after drug administration (sooner than most of the Schuckit studies), and thus
proposed a differentiator model, that high-risk individuals have
greater stimulant-like effects from alcohol during the ascending
limb of the breath alcohol curve and less sedative-like effects during the descending limb. Thus, the models are consistent, but the
differentiator model takes into account the biphasic nature of alcohol’s effects. Hendler et al. (2011) provide an in-depth review of
the variations in the stimulant and sedative effects of alcohol across
individuals, and how these may be related to future alcohol consumption. There is consensus that relative predictive value of these
proposals (low level response vs. differentiator model) will only be
resolved with further, in-depth longitudinal studies.
Taken together, these studies with alcohol provide some support for the idea that variation in initial responses to alcohol can
predict levels of future alcohol use. Yet, the ﬁndings are complex
and sometimes conﬂicting. Acute alcohol effects that are clearly
unpleasant (e.g., ﬂushing) appear to discourage drinking. Either
greater stimulant effects or lesser sedative effects appear to predict
escalation of drinking. Notably, however, alcohol challenge studies in the United States typically include participants 21 years of
age and older, whose responses may already be inﬂuenced by prior
experience. Assessing responses to alcohol at an earlier age would
provide more accurate measure of biological response and potential risk. Indeed, to the extent that early age of onset of drinking is a
predictor of future abuse (Grant, 1998; Moss et al., 2007), the ﬁrst
experiences of greatest importance may occur much earlier than 21
years of age. It is not even known whether acute response to alcohol is systematically related to age during the early, vulnerable ages.
Another limitation to the human alcohol challenge studies is that
most studies have tested healthy, young, usually Caucasian, volunteers without psychiatric or other substance disorders. Considering
the prevalence of psychiatric comorbidity between alcohol dependence and other psychiatric conditions, it would be of particular
interest to examine early responses to alcohol among individuals
with psychiatric disorders or dysregulated HPA function. It is also
likely that there are multiple trajectories to alcohol dependence
such as the type 1 higher functioning, environmentally inﬂuenced
alcoholism, and the type 2 male-predominant familial, severe alcoholism characterized by onset before age 25 (Cloninger et al., 1981).
A recent large-scale study suggested that there are as many as ﬁve
different subtypes, each with a distinctive etiology and trajectory
(Moss et al., 2007). Initial reactions to alcohol may play a different role in these subtypes (e.g., Gordh et al., 2011). Future research
on the relation between initial alcohol responses and alcohol use
disorders may help to reﬁne these subtypes and their biological
mechanisms.
3.1.2. Evidence from nonhumans
In nonhumans, metabolic factors have also been considered.
An Aldh type 2 knockout mouse that has high acetaldehyde levels
in blood, brain and liver after alcohol exposure (Isse et al., 2005),
exhibits a reduced preference for alcohol (Isse et al., 2002). Further,
alcohol has differential effects on Aldh type 2 gene expression in
different strains of mice, that correspond with their differences in
alcohol preference, indicating a genetic correlation between these
traits. A more modest correlation was found between Adh type
1 gene expression and alcohol preference in these mouse strains
(Tagliabracci and Singh, 1996). However, the role of these enzymes
in the brain appears to be more complicated, as there is also

evidence that these alcohol metabolizing enzymes in the brain may
play a positive role in the reinforcing effects of alcohol (Karahanian
et al., 2011). These authors suggest that alcohol serves as a
prodrug for acetaldehyde, and that acetaldehyde serves as the
active reinforcing drug. This builds on an older literature suggesting that acetaldehyde plays a role in alcohol self-administration
(e.g., Amit et al., 1977). In addition, metabolites of alcohol, such as
acetate, may be another source of variation in sensitivity to aversive
effects of alcohol that inﬂuences alcohol consumption (Maxwell
et al., 2010).
The animal alcohol literature provides mixed support for the
idea that alcohol sensitivity is associated with level of alcohol use.
As with the human ﬁndings just described, sensitivity in animals is
not a singular concept, and has been measured in many ways. For
example, one commonly used measure of alcohol sensitivity in animals is locomotor activity. Alcohol can either increase or decrease
locomotor activity, depending upon the dose of alcohol and the
time after alcohol administration at which behavior is measured.
Mice bred to have a greater locomotor stimulant response to alcohol early after administration (Crabbe et al., 1987; Phillips et al.,
2002) consume more alcohol (Risinger et al., 1994). To the extent
that locomotor activity represents stimulant-like positive effects,
this is consistent with the idea that greater sensitivity to positive
stimulant effects of alcohol predicts more alcohol use. Also, consistent with both the differentiator and low level of response models,
the higher alcohol consuming line of mice are less sensitive to the
sedative-hypnotic and some ataxic effects of alcohol (Shen et al.,
1996; Phillips et al., 2002; but see Boehm et al., 2000). In addition, using data from several laboratories collected in a panel of
inbred rat strains, a correlational approach and subsequent factor
analysis offered some support for a relationship between higher
alcohol intake and lower initial sensitivity to sedative-intoxicating
effects of alcohol (Spuhler and Deitrich, 1984). These ﬁndings,
taken together with data from inbred mouse strains, examining
sensitivity-intake relationships (Ozburn et al., 2010; Crabbe et al.,
2010) provide inconclusive evidence for the relation between initial
stimulant effects and subsequent alcohol consumption.
Lines of mice and rats have also been bred for their large
differences in alcohol consumption, but the ﬁndings have been
mixed, with regard to their initial sensitivity to alcohol. The low
level of response relationship with high intake has received some,
but not perfect, support for some sedative and ataxic effects of
alcohol (Colombo et al., 2000; Crabbe et al., 2010; Files et al.,
1996; Kurtz et al., 1996; Lumeng et al., 1982; Phillips and Crabbe,
1991; Schechter, 1992). Also, a relationship of a greater stimulant response with higher alcohol drinking has sometimes been
supported (Agabio et al., 2001; Krimmer, 1992; Krimmer and
Schechter, 1992; Quintanilla, 1999; Rodd et al., 2004; Waller et al.,
1986), but in other cases has not (Grahame et al., 2000; Paivarinta
and Korpi, 1993; Phillips et al., 2005, 1995). Some of the disparity is likely due to the genetic heterogeneity of alcohol drinking,
something that must be considered in outcomes from both humans
and nonhumans. For example, gene-speciﬁc research has identiﬁed
mechanisms that could underlie a relationship between alcohol
sensitivity and consumption (e.g., Hodge et al., 1999; Kim et al.,
2011; Naassila et al., 2002; Thiele et al., 2000). However, correspondence of sensitivity with consumption, not surprisingly, has not
been found for all genetic manipulations that have been examined
(Crabbe et al., 2006).
In rodent studies, conditioned aversive effects of alcohol
assessed soon after administration are negatively correlated with
consumption. Lines of rats and mice that were bred for higher
levels of alcohol consumption also exhibit reduced sensitivity to
the conditioned aversive effects of alcohol (Chester et al., 2003;
Froehlich et al., 1988; Quintanilla et al., 2001), and conversely, animals bred for greater conditioned aversion consumed less alcohol
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(Phillips et al., 2005). Similar results have been found in pairs, panels and crosses of inbred strains (Broadbent et al., 2002; Horowitz
and Whitney, 1975; Ozburn et al., 2010; Risinger and Cunningham,
1992; however, see Cailhol and Mormede, 2002; Risinger and
Cunningham, 1998). In general, although exceptions can be found
in the literature, the data suggest that there is a genetic relationship between these traits, and that sensitivity to the aversive effects
of alcohol serves as a protective factor against excessive alcohol
intake. In humans, the initial aversive effect of alcohol has not been
systematically studied as a predictor of future use, except in the
context of the ﬂushing response in Asians.
In nonhumans, information about the interoceptive effects of
alcohol, or how alcohol makes animals “feel”, is obtained using
drug discrimination methods. In these studies, the animal indicates whether an ingested or injected solution “feels” (or tastes)
like alcohol or not, usually by pressing an alcohol-associated
or non-alcohol-associated lever. The ﬁndings from these studies
examining the quality and magnitude of interoceptive effects of
alcohol in relation to the propensity to self-administer alcohol have
been mixed (Gordon et al., 1993; Krimmer, 1992; Krimmer and
Schechter, 1992; McMillan and Li, 1999, 2001; McMillan et al.,
1999; York, 1981). However, it was recently shown that chronic
exposure to the stress hormone corticosterone blunted the ability
of rats to identify alcohol (Besheer et al., 2012). This is consistent
with the idea that chronic stress may reduce the subjective effects
of alcohol in humans, leading an individual to consume more alcohol to achieve the desired effect.
3.2. Nicotine
3.2.1. Evidence from humans
Nicotine is a particularly interesting and paradoxical case for
examining the idea that initial, acute responses to drugs predict
progression to repeated use. Nicotine (or tobacco) is unique among
other drugs of abuse in that its initial subjective effects are typically not pleasant, and indeed often include unpleasant experiences
such as nausea and dizziness. As a result, it is often thought that
early use of tobacco is determined more by environmental inﬂuences (e.g., peer pressure) than by pleasant pharmacological effects.
Eissenberg and Balster (2000) reviewed the literature on early
responses to tobacco in relation to risk for regular smoking. Their
review included both retrospective studies assessing memories of
early responses among individuals who have tried smoking, as well
as longitudinal studies assessing early responses to smoking among
pre-adolescents and adolescents. There are several more recent
longitudinal studies, and there is also epidemiological evidence
relating cigarette smoking to variations in enzymes involved in the
metabolism of nicotine.
Several retrospective studies have examined participants’ recollections of their initial responses to smoking, as possible predictors
of progression. Haertzen et al. (1983) conducted an early retrospective study with opiate abusers who were asked to recall their
early experiences with nicotine and other drugs. Whereas they
reported pleasurable initial responses to heroin and cocaine which,
they claimed, inﬂuenced subsequent use, they remembered experiencing mainly unpleasant initial effects from tobacco, and that
these effects were unrelated to their subsequent smoking. In their
review of initial response as predictor of smoking, Eissenberg and
Balster (2000) found mixed results: in some studies, fewer dysphoric effects from initial cigarettes predicted smoking, whereas
in other studies more positive effects predicted future smoking.
More recently, DiFranza et al. (2004) interviewed 237 seventh
graders who had ever inhaled tobacco smoke, regarding their initial sensitivity to effects of nicotine. Relaxation was the strongest
predictor of progression to subsequent smoking, but surprisingly
and counter-intuitively, nausea, or dizziness also independently
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predicted progression. Similarly, Chen et al. (2003) surveyed 610
10th grade students who had ever tried smoking. After controlling for age and gender, pleasurable cigarette smell, pleasurable
buzz/rush, relaxation and dizziness predicted continued smoking.
The ﬁnding that pleasant cigarette smell was a predictor is interesting in light of preclinical evidence that nicotine may enhance
the value of environmental stimuli that have some motivational
value because of their association with primary rewards (Caggiula
et al., 2009; Chaudhri et al., 2006). Alternatively, it is possible that
cigarette smell was pleasant because of previous associations with
smoking (e.g., parents who smoked). Whether these remembered
initial responses to smoking were accurate, and whether they were
causally related to progression, cannot be determined from these
retrospective studies.
Several prospective studies have examined the relation between
initial sensations and later dependence. DiFranza et al. (2007) studied 217 sixth graders who had ever inhaled tobacco smoke, and
followed them for 4 years. They found that feelings of relaxation
after initial smoking predicted nicotine dependence, or “loss of
autonomy over smoking” and dependence (WHO, 1992) 4 years
later. Other predictors were familiarity with popular cigarette
advertisements (e.g., Joe Camel), novelty seeking and depressed
mood. Kandel et al. (2007) conducted a 2-year longitudinal study
with 353 6th to 10th graders who had tried a cigarette within the
year before the study or during the study. About 25% of the sample
developed Nicotine Dependence (APA, 1994) over a 2-year period,
and pleasant initial sensitivity to tobacco smoke was among the
best predictors of developing dependence. These authors took care
to obtain ratings of pleasantness and unpleasantness with regard to
sensations such as dizzy, rush, and buzz, and concluded that sensations that were regarded as pleasant were most predictive. Several
other studies have reported similar results (Audrain-McGovern
et al., 2007; Hu et al., 2006). More recently, Buchmann et al. (2011)
followed a cohort of German adolescents who had ever tried smoking, from age 15 until 22, to identify determinants of progression.
They found that earlier age of smoking was associated with more
pleasurable sensations from the ﬁrst cigarette and, although both
predicted progression to regular smoking, the age of smoking initiation was the more robust predictor of progression to dependence.
The question of whether the subjective or behavioral effects of
acute nicotine, or other drugs, vary with age, especially at younger
ages, is of critical importance and may explain differences in vulnerability. Ethical concerns about administering drugs to children
and adolescents make it unlikely that these important studies will
be done. Taken together, however, the prospective studies that
have been conducted add to the evidence that initial responses
to nicotine contribute to the likelihood of escalation from use to
dependence.
Perkins and colleagues have studied subjective responses to
acute nicotine in relation to consumption in controlled studies
in healthy volunteers (Perkins et al., 2001, 2000, 2008). In one
study (Perkins et al., 2001), nonsmokers sampled a nicotine nasal
spray, and then had the opportunity to ingest it again. Subjects who
reported more positive effects from the spray were more likely to
take it again, whereas subjects who experienced negative effects
were less likely to take it again. In another study (Perkins et al.,
2008), they examined subjects’ responses to intranasal nicotine
in relation to retrospective reports of early smoking experiences.
Adult nonsmokers who had smoked only 1–10 times in their lifetime and remembered feeling dizzy and buzzed from their ﬁrst
cigarette also reported these same effects after receiving nicotine
in a nasal spray. They described the effects as unpleasant, which
may have contributed to their non-continuation of smoking.
As is the case for alcohol, pharmacokinetic factors may inﬂuence
rates of smoking, and perhaps early responses to smoking (AudrainMcGovern et al., 2007; Ho and Tyndale, 2007). The metabolic
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inactivation of nicotine is controlled by genes such as CYP2A6 that
encodes a hepatic enzyme that affects most of the metabolism of
nicotine to cotinine (Benowitz and Jacob, 1994). Some studies have
reported that variations in this gene predict nicotine dependence:
slower metabolizers, who have genetic variants associated with
less than half of the activity of normal metabolizers, smoke fewer
cigarettes and are less likely to be current smokers (Malaiyandi
et al., 2006). However, this genetic relationship has not always
been found (Carter et al., 2004). Whether metabolic factors play
a role during early smoking experiences remains to be determined.
Audrain-McGovern et al. (2007) examined the role of pharmacokinetic variation in early onset of smoking, in adolescents from grades
9 to 12. Normal metabolizers progressed to nicotine dependence at
a faster rate than slow metabolizers, and these increases in nicotine dependence leveled off more slowly compared with slower
metabolizers. However, they found that initial subjective experiences from smoking were not related to the genotypes, nor were
they predictive of nicotine dependence.
Thus, the studies with early responses to nicotine provide
mixed evidence for the relation between early acute response and
smoking progression. Some studies found that initial feelings of
relaxation or pleasurable buzz predicted progression, whereas others found that dizziness and even nausea predicted future smoking.
Yet other studies found that early responses that were unpleasant decreased the likelihood of progression. These highly variable
ﬁndings suggest that early positive subjective responses to nicotine
may play a minor role in the development of smoking, and that perhaps magnitude of any subjective response (positive or negative)
may be predictive. Alternatively, other factors related to context,
learning and neurobiological adaptations may be more important
for this drug.
3.2.2. Evidence from nonhumans
In animals, nicotine also has competing positive and aversive
effects. Nicotine self-administration in animals has typically been
studied using intravenous (IV) methods, and dose-response curves
for IV self-administration have typically been inverted U-shaped,
reﬂecting lower dose positive effects through higher dose aversive
properties. Nicotine self-administration has been demonstrated in
several species (e.g., mice—Stolerman et al., 1999; rat—Corrigall
and Coen, 1989; Brower et al., 2002; dog—Risner and Goldberg,
1983; nonhuman primate—Sannerud et al., 1994). However, few
studies have examined the relationship between initial sensitivity to nicotine and nicotine intake. Recent reviews (Changeux,
2010; Tuesta et al., 2011) nicely detail current knowledge about
the involvement of speciﬁc nicotinic receptor subtypes, signaling
mechanisms and brain locations in nicotine, as well as other drug,
self-administration behavior, but does not touch on the topic of
initial sensitivity. However, there are genetic differences in sensitivity to behavioral effects of nicotine (Bergstrom et al., 2003;
Boyle and Gill, 2009; Gill and Boyle, 2005; Marks et al., 1989;
Overstreet, 1995; Tritto et al., 2004, 2002), which may affect selfadministration. Using inbred mouse strains varying in sensitivity to
the ﬁrst dose of nicotine, Robinson et al. (1996) examined whether
initial sensitivity corresponded with oral self-selection of nicotine,
when the animals were offered the choice of a nicotine-containing
solution vs. water or saccharin water. They found a strong negative genetic correlation between nicotine intake and sensitivity to
nicotine-induced seizures, suggesting that sensitivity to an apparently aversive effect of nicotine may limit intake. This relationship
deserves further more careful study in animal models.
As in the studies with humans, pharmacokinetic factors may
also affect nicotine self-administration in mice. Mice with greater
CYP2A5 protein levels (homologous with human CYP2A6 protein),
suggestive of an increased rate of nicotine metabolism, showed
increased nicotine self-administration (Siu et al., 2006). In addition,

rats of the Lewis strain have been found to self-administer more
nicotine than rats of the Fischer 344 strain, and they also appear
to have a more rapid nicotine clearance curve, and perhaps higher
initial peak levels of nicotine (Sziraki et al., 2001).
3.3. Cannabis
3.3.1. Evidence from humans
Both retrospective and prospective studies have examined the
relationship between initial responses to cannabis and subsequent
use of marijuana. Davidson and Schenk (1994) queried 197 college
students about memories of their initial experiences with marijuana, using a questionnaire describing both positive and negative
effects. Respondents who experienced more positive effects from
the drug the ﬁrst time had a shorter latency to their second use
as well as higher lifetime use. Although only a few respondents
reported negative effects from the drug, these negative ratings
did not predict use. Le Strat et al. (2009) conducted a retrospective analysis of 1472 young cannabis users in New Zealand and
France to investigate the positive and negative effects of cannabis
at ﬁrst use in relation to cannabis dependence at age 18–21. Participants rated the number of positive experiences from the cannabis
at initial use, from 1 to 5 positive responses (e.g., feeling high or
happy). The study found that the odds ratio of developing cannabis
dependence among respondents who reported 5 positive effects
was 28 times that of becoming dependent with no initial positive
effects, although the categorical classiﬁcation of ratings limits the
conclusions that can be drawn. Fergusson et al. (2003) conducted
a longitudinal study of 198 respondents who had used cannabis
before age 16, again using the ratings of 1–5 positive experiences.
Participants who reported 5 positive responses to cannabis at initial
use had an odds ratio of 28.5 for becoming dependent 4 years later,
compared to respondents who reported no positive effects. As in
the Davidson and Schenk (1994) study, negative experiences were
unrelated to future use. Taken together, these studies suggest that
positive subjective responses to initial marijuana experiences are
predictive of future use. It should be noted, however, that many
factors inﬂuence subjective responses to drugs, especially marijuana, including expectancies (Kirk et al., 1998), prior drug use and
personality (Chait and Perry, 1992). Thus, although early ratings of
liking marijuana appear to predict future use, the extent to which
this is based on the pharmacological response is not known. This
would only be answerable with controlled studies in which the drug
could be administered for the ﬁrst time under double blind conditions, which is unlikely to occur. This problem with expectances
also applies to the ﬁrst use of other classes of drugs in a naturalistic
situation, where users almost always have expectancies regarding
the drug’s identity and its effects.
3.3.2. Evidence from nonhumans
The natural cannabinoid, delta(9)-tetrahydrocannabinol (THC),
and synthetic and endogenous cannabinoid receptor agonists such
as, WIN 55212-2 and anandamide, are self-administered by animals (monkeys—Justinova et al., 2008; Tanda and Goldberg, 2003;
Tanda et al., 2000; rats—Fattore et al., 2001; Lecca et al., 2006;
mice—Mendizabal et al., 2006). However, some have argued that
cannabinoids are atypical in preclinical animal models with regard
to their proﬁles as drugs of abuse, because the experimental
conditions under which motivational and reinforcing effects are
displayed are more restricted than for other drugs of abuse (Panagis
et al., 2008). Stimulant and depressant responses to acute cannabinoids have been recorded (Bass et al., 2002; Darmani, 2001;
Meschler et al., 2000; Varvel et al., 2007; Wiley et al., 2008), as
have aversive effects (McGregor et al., 1996; Murray and Bevins,
2010). Further, the role of endogenous endocannabinoids and
their receptors more generally in drug reinforcement and other
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addiction-related behaviors (Serrano and Parsons, 2011), and in
stress associated responses (Dubreucq et al., 2012; Riebe and
Wotjak, 2011), has more recently received considerable attention.
However, the question of whether initial sensitivity to cannabinoids predicts level of cannabinoid intake does not appear to have
been addressed in animal models of cannabinoid use. This is perhaps partly because self-administration of cannabinoids has been
more difﬁcult to reliably establish in animal models compared to
self-administration of most other addictive drugs.
3.4. Cocaine and other stimulants
3.4.1. Evidence from humans
A few retrospective studies have examined initial response to
cocaine or other stimulants as a predictor of future use. In one
early study (Haertzen et al., 1983) opiate abusers claimed that initially positive responses to cocaine predicted their later use of the
drug. Davidson et al. (1993) interviewed 44 college students who
reported having used cocaine and found that positive responses
to the drug on initial use predicted a shorter latency to the second use. Negative effects did not predict future use. More recently,
Lambert et al. (2006) conducted a study with 202 adults who had
tried cocaine at least once between ages 16 and 40. Participants
who reported ‘liking’ and ‘wanting’ the drug upon initial exposure
to cocaine were more likely to develop cocaine dependence and
life-time cocaine abuse.
Many laboratory-based studies have examined subjective responses to stimulant drugs such as amphetamine and
methylphenidate in healthy volunteers, in relation to consumption
or choice (Chait, 1993; de Wit et al., 1986; Holdstock and de Wit,
2001; Johanson and Uhlenhuth, 1980; Kollins et al., 2001; Lott
et al., 2005; Rush et al., 2001; Volkow et al., 1999). Healthy young
adults vary in their ratings of arousal, liking and anxiety after
low doses of amphetamine. These studies consistently show that
pleasurable, stimulant-like subjective effects are directly related to
consumption of the drug, within the experimental context. In the
studies with amphetamine, most participants experience positive
mood effects from amphetamine during their ﬁrst experiences
with them, but a small minority experience unpleasant effects such
as anxiety. The mood effects of the drug clearly predict whether
subjects will choose to take the drug again when they are given the
opportunity, on subsequent study sessions. These studies provide
strong support for the idea that pleasurable initial responses are
related to subsequent drug-taking, albeit in the limited context and
abbreviated time frame of a laboratory research study. These acute
drug challenge studies may help to identify risk factors predicting
future use, including genetic factors (Hart et al., 2012; Lott et al.,
2005), personality and psychiatric symptoms (de Wit and Bodker,
1994; de Wit et al., 1987), expectancies (Mitchell et al., 1996) and
brain dopamine receptor density (Volkow et al., 1999). The studies
show systematic relations between acute drug responses and drug
choice in the laboratory.
3.4.2. Evidence from nonhumans
In rats, using genetically heterogeneous groups of animals, locomotor response to an acute dose of a psychostimulant may predict
consumption of the drug. For amphetamine, greater acute sensitivity to locomotor effects of the drug was associated with higher
levels of self-administration (Deminiere et al., 1989; Piazza et al.,
1989). This relationship has also been found for cocaine in some,
but not all, studies (Mandt et al., 2012, 2008; Mantsch et al., 2001).
When approaches have been used that directly investigate potential genetic relationships between sensitivity and intake, evidence
has also been mixed. In a panel of inbred mouse strains, postprandial drinking of cocaine and sensitivity to the stimulant effects
of cocaine were not strongly related (Seale and Carney, 1991).
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However, in rat lines selectively bred for high vs. low locomotor
activity in a novel environment, the high activity line rats exhibited a higher propensity to self-administer cocaine (Cummings
et al., 2011; Davis et al., 2008) and greater sensitivity to quinpirole (Flagel et al., 2010), a dopamine D2/D3 receptor agonist, which
would be thought to partly mimic the effects of cocaine. Unfortunately, to the best of our knowledge, drug sensitivity has not
been fully characterized in these lines, although one study showed
no difference between the lines in activation to an initial treatment with a 15 mg/kg dose of cocaine (Garcia-Fuster et al., 2010).
A mouse line selectively bred for higher oral intake of methamphetamine (Shabani et al., 2011; Wheeler et al., 2009) that also
exhibits greater operant methamphetamine self-administration
(Shabani et al., 2012a) exhibits greater acute locomotor activation to methamphetamine (Shabani et al., 2011). However, mice
bred for extreme sensitivity to the stimulant effects of methamphetamine voluntarily consume less methamphetamine compared
to the oppositely selected low stimulation line (Kamens et al.,
2005). The authors suggest two interpretations. First, the mice bred
for high stimulation may require less MA to experience rewarding effects and thus, may choose to consume less MA compared to
the mice bred for low stimulation. Alternatively, extreme sensitivity to the stimulant effect could be aversive, and thus, avidity for
methamphetamine is reduced. The positive association of methamphetamine intake and stimulation in the lines bred for high and low
MA drinking was seen only at a higher 4 mg/kg dose, whereas the
stimulation selected lines were bred based on their response to
2 mg/kg methamphetamine. It is possible that the use of the lower
dose resulted in a more profound sensitivity, as one would expect
to identify more sensitive animals with this low dose, than with a
higher dose.
In addition to the association of sensitivity to stimulant effects
with intake, aversive effects of methamphetamine have been studied. Mice bred for low drinking of methamphetamine solutions
showed profound conditioned aversion induced by a single treatment with methamphetamine that was not seen in the high
drinking line mice, even after multiple treatments (Shabani et al.,
2012b; Wheeler et al., 2009). These results are similar to those for
alcohol, and suggest that high sensitivity to the aversive effects of
methamphetamine protects against high levels of intake.
Another source of information about initial responses to drugs
and drug-taking in animal models comes from studies of discriminative stimulus effects. For example, rats that were more
sensitive to the activating effects of amphetamine were also
more sensitive to its discriminative stimulus effects (Bevins et al.,
1997). In a study in non-human primates investigating cocaine
self-administration and drug discrimination, at least one dose supported only self-administration without serving as a discriminative
stimulus. This suggests that cocaine reinforcement can occur in the
absence of a cocaine-like discriminative stimulus effect (Martelle
and Nader, 2009). However, once a drug has been established as
a discriminative stimulus, it can substantially increase subsequent
self-administration (Panlilio et al., 1996). Thus, sensitivity to drug
discriminative stimulus effects has the potential to inﬂuence drug
intake.
3.5. Caffeine
3.5.1. Evidence from humans
In an early retrospective study, Haertzen et al. (1983) queried
opiate abusers about their initial responses to caffeine. Although
these participants claimed that their initial responses to heroin and
cocaine predicted subsequent use of these drugs, they reported that
their initial responses to caffeine were unpleasant and not related
to future use. To our knowledge, no longitudinal studies have examined the initial responses to caffeine in relation to future use. One
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challenge to conducting longitudinal studies on early responses
to caffeine is that caffeine use begins early (Frary et al., 2005),
usually in the form of caffeinated sodas. Because of the widespread
use of these drinks and the relatively subtle acute effects of low
doses of caffeine, it is difﬁcult to assess early responses under noncontrolled conditions.
Several laboratory-based studies have examined acute subjective responses to caffeine in adults as predictors of choice or
consumption of the drug in the laboratory (Grifﬁths and Woodson,
1988; Stern et al., 1989). These studies support the idea that pleasant caffeine-induced effects such as mental arousal and decreased
fatigue predict drug choice, whereas unpleasant effects such as
jitteriness or anxiety predict non-choice of caffeine. There is also
indirect evidence that negative subjective responses predict low
caffeine use. Patients with panic disorder experience anxiety from
caffeine, and consume less of it than healthy controls (Boulenger
et al., 1984; Charney et al., 1985; Lee et al., 1988; Uhde et al., 1984).
Moreover, in both panic disorder patients and healthy controls,
individuals with a certain polymorphism of the adenosine receptor
gene are more likely to experience anxiety from an acute dose of the
drug (Alsene et al., 2003; Charney et al., 1985; Childs et al., 2008; Lee
et al., 1988; Uhde et al., 1984). Yang et al. (2010) recently reviewed
evidence for the contribution of genetic factors in responses to
caffeine in humans and found evidence for genetic contributions
to the positive vs. negative subjective or physiological effects of
caffeine (e.g., feelings of arousal, anxiety or insomnia), level of
habitual caffeine consumption and caffeine metabolism. Indeed,
recent genome-wide association analyses involving thousands of
people have identiﬁed signiﬁcant associations with caffeine intake
for single nucleotide polymorphisms that suggest a role for genes
involved in the metabolism of caffeine or the constituents of coffee
(Amin et al., 2011; Cornelis et al., 2011; Sulem et al., 2001). Whether
there is a role for these genes in caffeine sensitivity has not been
explored.
3.5.2. Evidence from nonhumans
Relatively few studies have examined initial acute responses to
caffeine in relation to self-administration in nonhumans. However,
mechanistic studies point to a role for the A2A receptor subtype in
both caffeine consumption and locomotor activation (El Yacoubi
et al., 2000, 2005; Yang et al., 2009), using A2A knockout mice.
In another study using A1 knockout mice, no evidence for a role
of the A1 receptor subtype in caffeine consumption was found
(Rieg et al., 2007) and a lesser role than that of the A2A receptor was found for caffeine-induced locomotor stimulation (Yang
et al., 2009). Though these are interesting results that suggest some
common mechanisms underlying sensitivity and intake, they do
not directly address the question of whether initial sensitivity to
caffeine predicts future intake.

in relation to subsequent abuse, although such information would
be valuable because of the widespread medical use of opiates as
well as the recently increasing prevalence of abuse (Manubay et al.,
2011; Maxwell, 2011). Fortunately, only a very small proportion of
patients who receive opiates for pain control progress to develop
problems with abuse (Hojsted and Sjogren, 2007).
Controlled studies with healthy volunteers do indicate that
acute responses to opiates vary markedly across individuals (Comer
et al., 2010; Lasagna et al., 1955; McAuliffe, 1975; Zacny and
Gutierrez, 2003; Zacny et al., 1994, 1992), from pleasant to unpleasant. Whether these initial subjective effects of opiates predict
repeated use or choice over a placebo has not yet been studied.
3.6.2. Evidence from nonhumans
The question of the relationship between initial sensitivity and
self-administration of opiates has received relatively little attention in nonhuman studies. C57BL/6J inbred strain mice exhibit a
larger initial stimulant response to morphine than do DBA/2J mice
(Belknap et al., 1989), and DBA/2J mice exhibit a locomotor depressant response to morphine early after administration (Phillips
et al., 1994). Consistent with the idea that stimulation is related
to reward, morphine supports intravenous self-administration in
C57BL/6J, but not DBA/2J mice (Elmer et al., 2010). These data
are in agreement with two-bottle choice drinking studies showing greater morphine consumption in the C57BL/6J than DBA/2J
strain (Belknap et al., 1993; Horowitz et al., 1977). Thus, for these
two strains, the data suggest that greater initial sensitivity to stimulant effects of an opioid is associated with greater reinforcement,
and greater sensitivity to depressant effects reduces consumption. However, in another set of 4 strains, oral self-administration
of the opioid, etonitazene, was not associated with sensitivity
to etonitazene-induced locomotor stimulation or other effects
(Elmer et al., 1995). A few studies in single gene mutant mice
are also relevant. Not surprisingly, mu-opioid receptor knockout
mice do not self-administer morphine and show reduced sensitivity to morphine-induced locomotor stimulation (Sora et al.,
2001). In mice lacking protein kinase C epsilon, increased susceptibility to morphine self-administration was associated with
enhanced sensitivity to morphine’s analgesic effects, compared to
their non-mutant counterparts (Newton et al., 2007). Mice lacking
the NK1 receptor, the preferred receptor for substance P, exhibited
heightened sensitivity to locomotor depressant effects of morphine, as well as reduced self-administration of morphine (Ripley
et al., 2002). These results mirror those for DBA/2J, compared to
C57BL/6J, mice. Overall, the data support a positive relationship
between sensitivity to stimulant effects of opioids and opioid selfadministration and a negative relationship between sensitivity to
depressant effects of opioids and opioid self-administration.

3.6. Opiates

4. Conclusions

3.6.1. Evidence from humans
In an early retrospective study, Haertzen et al. (1983) reported
that opiate abusers liked their ﬁrst experiences with heroin and
other opiates more than they liked 11 other types of drugs that
they had used, and that opiates were their preferred and primary
drug of choice from the beginning. Conducting a retrospective study
that included non-drug-abusing volunteers, Bieber et al. (2008)
recruited 20 opioid abusers in a treatment center and 20 controls,
all of whom had ﬁrst received opiates for pain control. Participants
completed a retrospective questionnaire reporting the feelings of
euphoria and well-being they experienced upon their ﬁrst use of an
opiate drug. The drug-abusing participants reported having experienced greater euphoria upon their ﬁrst use than the control group.
There are no longitudinal studies on initial responses to opiates

So, do initial responses to drugs predict future use or abuse? We
have reviewed the limited evidence that early responses to drugs
predict use or abuse in humans and nonhumans. First, we conﬁrm that there are marked individual differences in initial acute
responses to drugs, and some of these differences are genetic.
Second, we conﬁrm that certain direct effects of drugs appear to
be protective against future use, such as, in humans, the ﬂushing
response to alcohol and perhaps the anxiety response to caffeine.
Third, we ﬁnd some evidence that euphoria and stimulation facilitate repeated use across several classes of drugs, including opiates
and stimulants in humans, although the evidence for stimulants in
animals is more mixed. From this review, we conclude that initial
positive or negative effects of drugs probably inﬂuence the likelihood of continuing use in the short term, but their relationship with
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full dependence is less clear. By deﬁnition, early use must precede
escalation of use, which precedes dependence. Therefore, there is
likely to be some relation between initial responses and dependence. However, the contribution of the initial acute effect of the
drug is probably minor, compared to the multitude of other variables that contribute to excessive drug use. These include cognitive
factors related to decision-making, physiological factors related to
stress, as well as processes of neural adaptation, learning, tolerance,
sensitization, and physical dependence that only develop with continued ingestion of the drugs.
We have identiﬁed gaps in the literature, methodological challenges and directions for future research. Longitudinal research
documenting initial drug effects, and following probands across
their drug-taking trajectories, is the gold standard. Longitudinal
studies would be of particular interest with opiates, for example,
and with cigarette smokers. Animal models also offer a valuable tool
for studying this relationship, and for particular studying genetic
factors. Initial drug responses can easily be obtained in naïve animals, genetic characteristics and context can be controlled and drug
dose and purity are not an issue. Relatively few nonhuman studies
have followed the complete time progression of the dependence
process, beyond the initial self-administration period. To coordinate the human and nonhuman studies, there is a need to develop
and reﬁne drug-abuse related measures that are directly comparable in humans and animals (Crabbe et al., 2010; O’Dell and Khroyan,
2009; Stephens et al., 2011). Although the relationship between initial drug sensitivity and risk for abuse or dependence is not likely
to be simple, further exploration is likely to solidify which traits are
of greatest relevance and thus, of greatest predictive value.
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